CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES FOR HOSPITALS
California Cancer Reporting System Standards, Volume I

SUMMARY OF YEAR 2021 DATA CHANGES

This document provides a summary of data changes for 2021 for hospitals, abstracting vendors, and regional registry data collectors. The updated Volume I for 2021 will be available as soon as possible, after receiving standard setter requirements and documentation. This document is divided into sections – Additions (New Data Items), Changes (Revised Data Items), Retired (Retired Data Items), and Additional Updates (other Volume I related items for cases diagnosed January 1, 2021 and forward).

NAACCR ADDITIONS (New Data Items):
There are 26 data items that are new for Standards Volume II, Version 21 as follows:
- 5 Site-Specific Data Items (SSDIs)
- 3 Neoadjuvant Data Items
- 13 Staging Data Items:
    - 6 AJCC TNM Post Therapy Clin (yc) Items *(Previous AJCC TNM Post Therapy items have been revised to AJCC TNM Post Therapy Path (yp) items. These will be noted in the Changed Data items section).*
    - 1 Grade Post Therapy (yc) Item *(Previous Grade Post Therapy has been revised to the Grade Post Therapy Path (yp) item. This will be noted in the Changed Data items section).*
    - 4 AJCC API Version Items *(generated by software)*
    - 2 SEER Staging API Items *(generated by software)*
- 4 NCDB COVID-19 Items
- 1 Demographic Data Item

Details of the above new data fields are outlined below:

Demographics

Name--Birth-Surname   **NAACCR Item #2232**
Field Length: 40 characters   **Source of Standard: NAACCR**

Name--Birth Surname will be replacing the existing Name--Maiden. This is a gender-neutral last name (surname) of the patient at birth, regardless of gender or marital status. Other alternate names should continue to be recorded in the data item, Nam--Alias.

Stage

AJCC Post Therapy Clin (yc) M   **NAACCR Item #1066**
Field Length: 15 characters   **Source of Standard: AJCC**

Detailed site-specific code for post therapy clinical (yc) metastasis (M) as defined by AJCC. AJCC will provide education on the appropriate use of the yc TNM data items.

Codes (in addition to those published in the AJCC Cancer Staging Manual)
88   Not applicable, no code assigned for this case in the current AJCC Staging Manual
Blank   This field is left blank if no information at all is available to code this item.

AJCC TNM Post Therapy Clin (yc) N   NAACCR Item #1064
Field Length: 15 characters   **Source of Standard: AJCC**
Detailed site-specific codes for the post therapy clinical (yc) nodes (N) as defined by AJCC. AJCC will provide education on the appropriate use of the yc TNM data items.

Codes (in addition to those published in the AJCC Cancer Staging Manual)
88   Not applicable, no code assigned for this case in the current AJCC Staging Manual
Blank   This field is left blank if no information at all is available to code this item.

AJCC TNM Post Therapy Clin (yc) N Suffix   NAACCR Item #1065
Field Length: 4 characters   **Source of Standard: AJCC**
Detailed site-specific codes for the post therapy clinical (yc) N category suffix as defined by AJCC. AJCC will provide education on the appropriate use of the yc TNM data items.

Codes
(sn)   Sentinel node procedure without resection of nodal basin
(f)   FNA or core needle biopsy without resection of nodal basin
Blank   No suffix needed or appropriate; not recorded

AJCC TNM Post Therapy Clin (yc) Stage Group   NAACCR Item #1067
Field Length: 15 characters   **Source of Standard: AJCC**
Detailed site-specific codes for the post therapy clinical (yc) stage group as defined by AJCC. AJCC will provide education on the appropriate use of the yc TNM data items.

Codes (in addition to those published in the AJCC Cancer Staging Manual)
88   Not applicable, no code assigned for this case in the current AJCC Staging Manual
99   Unknown, not staged

AJCC TNM Post Therapy Clin (yc) T   NAACCR Item #1062
Field Length: 15 characters   **Source of Standard: AJCC**
Detailed site-specific codes for the post therapy clinical (yc) tumor (T) as defined by AJCC. AJCC will provide education on the appropriate use of the yc TNM data items.

Codes (in addition to those published in the AJCC Cancer Staging Manual)
88   Not applicable, no code assigned for this case in the current AJCC Staging Manual
Blank   This field is left blank if no information at all is available to code this item.

AJCC TNM Post Therapy Clin (yc) T Suffix   NAACCR Item #1063
Field Length: 4 characters   **Source of Standard: AJCC**
Detailed site-specific codes for the post therapy clinical (yc) tumor T category suffix as defined by AJCC. AJCC will provide education on the appropriate use of the yc TNM data items.

Codes (as published in the AJCC Cancer Staging Manual)

(m)	Multiple synchronous tumors OR for thyroid differentiated as anaplastic only, Multifocal tumor
(s)	For thyroid differentiated and anaplastic only, Solitary tumor
Blank	No information available; not recorded

Grade Post Therapy Clin (yc)   NAACCR Item #1068
Field Length: 1 character   **Source of Standard: NAACCR**

This data item records the grade of a solid primary tumor that has been microscopically sampled following neoadjuvant therapy or primary systemic/radiation therapy.

Codes (Refer to the most recent version of the SSDI Manual for additional site-specific instructions)

Neoadjuvant Therapy   NAACCR Item #1632
Field Length: 1 character   **Source of Standard: SEER**

This data item records whether the patient had neoadjuvant therapy prior to planned definitive surgical resection of the primary site.

Codes

0	No neoadjuvant therapy, no treatment before surgery, surgical resection not part of first course of treatment plan
	Autopsy only
1	Neoadjuvant therapy completed according to treatment plan and guidelines
2	Neoadjuvant therapy started, but not completed OR unknown if completed
3	Limited systemic exposure when the intent was not neoadjuvant; treatment did not meet the definition of neoadjuvant therapy
9	Unknown if neoadjuvant therapy performed
	Death Certificate only (DCO)

Neoadjuvant Therapy-Clinical Response   NAACCR Item #1633
Field Length: 1 character   **Source of Standard: SEER**

This data item records the clinical outcomes of neoadjuvant therapy prior to planned surgical resection.

Codes

0	Neoadjuvant therapy not given
1	Complete clinical response (CR)(per managing/treating physician statement)
2	Partial clinical response (PR) (per managing/treating physician statement)
3	Progressive disease (PD)(per managing/treating physician statement)
4	Stable disease (SD)(per managing/treating physician statement)
5	No response (NR) (per managing/treating physician statement
	Not stated as progressive disease (PD) or stable disease (SD)
6	Neoadjuvant therapy done, managing/treating physician interpretation not available, treatment response inferred from imaging, biomarkers, or yc stage
7	Complete clinical response based on pathology report (per pathologist assessment)
8	Neoadjuvant therapy done, response not documented or unknown
9	Unknown if neoadjuvant therapy performed
	Death Certificate only (DCO)

Neoadjuvant Therapy-Treatment Effect   NAACCR Item #1634
Field Length: 1 character   **Source of Standard: SEER**

This data item records the pathologist's statement of neoadjuvant treatment effect on the primary tumor from the surgical pathology report.

Codes

0	Neoadjuvant therapy not given/no known presurgical therapy
1-4	Site-specific code; type of response
6	Neoadjuvant therapy completed and surgical resection performed, response not documented or unknown
	Cannot be determined
7	Neoadjuvant therapy completed and planned surgical resection not performed
9	Unknown if neoadjuvant therapy performed
	Unknown if planned surgical procedure performed after completion of neoadjuvant therapy
	Death Certificate only (DCO)

Site Specific Data Items (SSDIs)

Five new Site-Specific Data Items Beginning with cases diagnosed 1/1/2021 have been added to the SSDI Manual. For additional information and coding instructions, please see the SSDI Manual located on the NAACCR website. The list of new SSDI's and applicable Schemas are listed below for your convenience.

Site-Specific Data Items (SSDIs) – New Items List
Source of Standard: NAACCR

NAACCR Name	Schema	NAACCR Item #	Field Length (characters)
ALK Rearrangement	Lung (00360)	3938	1
BRAF Mutational Analysis	Colon and Rectum (00200)	3940	1
CA 19-9 PreTx Lab Value	Pancreas (00280)	3942	6
EGFR Mutational Analysis	Lung (00360)	3939	1
NRAS Mutational Analysis	Colon and Rectum (00200)	3941	1

Versioning Data Items

AJCC API Version Current   **NAACCR Item #2156**
Field Length: 8 characters   **Source of Standard: AJCC**
This item indicates the version of the AJCC TNM API incorporated into the cancer registry software that created the record with TNM staging data in the 8th and later versions. This data item will be generated by registry software.

AJCC API Version Original   **NAACCR Item #2157**
Field Length: 8 characters   **Source of Standard: AJCC**
This item indicates the version of the AJCC API incorporated into the cancer registry software that created the record with TNM stage data in the 8th and later versions. This data item will be generated by registry software.

[AJCC Cancer Surveillance API Version Current](#)   [NAACCR Item #2158](#)

Field Length: 13 characters   **Source of Standard: AJCC**

This item indicates the most recently accessed version of the Cancer Surveillance .dll incorporated into the cancer registry software that created the record with stage data diagnosed 2018 and later. This data item will be generated by registry software.

[AJCC Cancer Surveillance API Version Original](#)   [NAACCR Item #2159](#)

Field Length: 13 characters   **Source of Standard: AJCC**

This item indicates the version of the AJCC Cancer Surveillance .dll incorporated into the cancer registry software that created the record with stage data diagnosed 2018 and later. This data item will be generated by registry software.

[Schema ID Version Current](#)   [NAACCR Item #2117](#)

Field Length: 5 characters   **Source of Standard: SEER**

This item indicates the version of EOD component of the SEER Staging API used to assign the 2018 and later staging fields of Schema ID, Grades, EOD input fields, SS2018, and SSDIs. This data item will be generated by registry software.

[Schema ID Version Original](#)   [NAACCR Item #2118](#)

Field Length: 5 characters   **Source of Standard: SEER**

This item indicates the version of EOD component of the SEER Staging API used to assign the 2018 and later staging fields of Schema ID, Grades, EOD input fields, SS2018, and SSDIs. This data item will be generated by registry software.

Other Data Items

[NCDB--COVID19--Tx Impact](#)   [NAACCR Item #3946](#)

Field Length: 1 character   **Source of Standard: CoC**

Was the first course of treatment (diagnosis, staging, treatment or other cancer management events) impacted by hospital availability (limited access to facilities or postponement of non-essential procedures) due to COVID-19 pandemic? (No; First Course Delayed; First Course Altered; First Course Cancelled). Collection based on diagnosis years 2020 and 2021.

Codes

1	Treatment not affected; active surveillance, no change
2	First Course of Treatment timeline delayed
3	First Course of Treatment plan altered
4	Cancelled First Course of Treatment
5	Patient refused treatment due to COVID-19
9	Not known if treatment affected

[NCDB--SARSCoV2--Pos](#)   [NAACCR Item #3944](#)

Field Length: 1 character   **Source of Standard: CoC**

Data item is designed to track whether patient received a POSITIVE SARS-CoV-2 test or not. Collection based on diagnosis years 2020 and 2021.

Codes

0	Patient did not test positive for active SARS-CoV-2: No positive test
1	Patient tested positive for active SARS-CoV-2: test positive on at least one test
9	Unknown if tested; test done, results unknown

NCDB--SARSCoV2--Pos Date   NAACCR Item #3945
Field Length: 8 characters   **Source of Standard: CoC**

What was the date of the first positive test? Collection based on diagnosis years 2020 and 2021.

Codes

YYYYMMDD	Date the patient had a positive test for SARS-CoV-2, the virus that causes the 2019 novel coronavirus disease (COVID-19), as documented by a medical provider
Blank	Date of the test is unknown or the date of a positive (diagnostic or serologic) test is unknown for SARS-CoV-2

NCDB--SARSCoV2--Test   NAACCR Item #3943
Field Length: 1 character   **Source of Standard: CoC**

Data item is designed to track whether patient received a SARS-CoV-2 test or not. Collection based on diagnosis years 2020 and 2021.

Codes

0	Patient not tested for SARS-CoV-2: facility records support that patient did not undergo pre-admit or in-hospital testing
1	Patient tested positive for Active SARS-CoV2
9	Unknown if patient tested for SARS-CoV-2/No facility record of preadmit hospital testing of SARS-CoV-2

NAACCR CHANGES (Revised Data Items):

Listed below are revisions made in the NAACCR Volume II, Standards and Data Dictionary for 2021. It has been separated into General Changes and Specific Changes.

General Changes:

1. As part of the 2021 update, the NAACCR XML Data Exchange Standard was adopted as the standard transmission format, and the NAACCR fixed-width format has been retired.
2. Effective with 2021, data transmission using column-designated flat files will no longer be supported by NAACCR.
3. Reference manual links have been updated throughout the Data Dictionary.
4. Minor formatting updated throughout the Data Dictionary.
5. Field length changes:

Field Length Change – List
Source of Standard: N/A

NAACCR Name	NAACCR Item #	Field Length changed from:	Field Length changed to:
FIGO Stage	3836	2	5
Medical Record Number	2300	11	15

Specific Changes:

AJCC TNM Post Therapy Path (yp) M   NAACCR Item #1023

Field Length: 15 characters   **Source of Standard: AJCC**

Name changed from AJCC TNM Post Therapy to AJCC TNM Post Therapy Path (yp) M to differentiate it from the new AJCC Post Therapy Clin (yc) M item.

AJCC TNM Post Therapy Path (yp) N   NAACCR Item #1022

Field Length: 15 characters   **Source of Standard: AJCC**

Name changed from AJCC TNM Post Therapy N to AJCC TNM Post Therapy Path (yp) N to differentiate it from the new AJCC Post Therapy Clin (yc) N item.

AJCC TNM Post Therapy Path (yp) N Suffix   NAACCR Item #1036

Field Length: 4 characters   **Source of Standard: AJCC**

Name changed from AJCC TNM Post Therapy N Suffix to AJCC TNM Post Therapy Path (yp) N Suffix to differentiate it from the new AJCC Post Therapy Clin (yc) N Suffix item.

AJCC TNM Post Therapy Path (yp) Stage Group   NAACCR Item #1024

Field Length: 15 characters   **Source of Standard: AJCC**

Name changed from AJCC TNM Post Therapy Stage Group to AJCC TNM Post Therapy Path (yp) Stage Group to differentiate it from the new AJCC TNM Post Therapy Clin (yc) Stage Group item.

AJCC TNM Post Therapy Path (yp) T   NAACCR Item #1021

Field Length: 15 characters   **Source of Standard: AJCC**

Name changed from AJCC TNM Post Therapy T to AJCC TNM Post Therapy Path (yp) T to differentiate it from the new AJCC TNM Post Therapy Clin (yc) T item.

AJCC TNM Post Therapy Path (yp) T Suffix   NAACCR Item #1033

Field Length: 4 characters   **Source of Standard: AJCC**

Name changed from AJCC TNM Post Therapy T Suffix to AJCC TNM Post Therapy Path (yp) T Suffix to differentiate it from the new AJCC TNM Post Therapy Clin (yc) T Suffix item.

CoC Accredited Flag   NAACCR Item #2152

Field Length: 2 characters   **Source of Standard: NPCR**

The following sentence was added to the end of the "Rationale" paragraph: The flag also allows cases to be stratified during analyses to identify those never seen at a CoC-accredited facility; e.g., percentage of all cases seen in at least one CoC-accredited facility, evaluation of outcomes by facility status. NPCR will use this flag for facility status stratification.

CoC Coding Sys--Current   NAACCR Item #2140
CoC Coding Sys--Original   NAACCR Item #2150

Field Length: 2 characters   **Source of Standard: CoC**

Documentation under topics "Description" was updated to reflect that the data item is no longer required by the CoC.

EOD Prostate Pathological Extension   NAACCR Item #3919
Field Length: 3 characters   **Source of Standard: NAACCR**

Name changed from Prostate Pathological Extension to EOD Prostate Pathological Extension to clarify that the field is part of EOD 2018.

Grade Post Therapy Path (yp)   NAACCR Item #3845
Field Length: 1 character   **Source of Standard: NAACCR**

Name changed from Grade Post Therapy to Grade Post Therapy (yp) to differentiate it from the new Grade Post Therapy Clin (yc) item.

Morph Coding Sys--Current   NAACCR Item #470
Field Length: 1 character   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to add a new codes A and B. The code updates and additions are as follows:

Codes

A	ICD-O, Third Edition, plus WHO new terms used for conditions, effective 1/1/2018
B	ICD-O 3.2, effective 1/1/2021

Morph Coding Sy--Originl   NAACCR Item #480
Field Length: 1 character   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to add a new codes A and B. The code updates and additions are as follows:

Codes

A	ICD-O, Third Edition, plus WHO new terms used for conditions, effective 1/1/2018
B	ICD-O 3.2, effective 1/1/2021

NAACCR Record Version   NAACCR Item #50
Field Length: 3 characters   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to add a new codes 210. The code updates and additions are as follows:

Codes

210	2021 Version 21

Name--Alias   NAACCR Item #2280
Field Length: 40 characters   **Source of Standard: NAACCR**

Description updated to refer to Name--Birth Surname in place of Name--Maiden, as an alternate name that should **not** be entered in Name--Alias.

Name--Maiden   NAACCR Item #2390
Field Length: 40 characters   **Source of Standard: NAACCR**

Name--Birth Surname will take the place of Name--Maiden. It is planned that Name--Maiden will be retired in 2022.

Medical Record Number   NAACCR Item #2300
Field Length: 15 characters   **Source of Standard: NAACCR**

The field length has been updated from 11 to 15.

Phase I Radiation Treatment Modality   **NAACCR Item #1506**
Phase II Radiation Treatment Modality   **NAACCR Item #1516**
Phase III Radiation Treatment Modality   **NAACCR Item #1526**
Field Length: 2 characters   **Source of Standard: CoC**

Allowable values have been modified. Essentially, code 98 has been added to differentiate cases where it is known radiation was given, but modality is unknown. Code 99 is only used when it is unknown if radiation was given. This change is to be used for all cases abstracted after the v21 implementation regardless of diagnosis year.

Codes

98	Radiation therapy administered but treatment modality is not specified or unknown
99	Unknown if radiation treatment administered

RQRS NCDB Submission Flag   **NAACCR Item #2155**
Field Length: 1 character   **Source of Standard: CoC**

Documentation under topic "Codes" was updated to state: " As of 01/01/2021, this item will no longer be required by the CoC.

RX Coding System--Current   **NAACCR Item #1460**
Field Length: 2 characters   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated and missed by CCR with 2018 Data Changes to include a new code 08. The code updates and additions are as follows:

Codes

08	Treatment data coded according to *STORE* Manual and 2018 SEER Coding Manual

SEER Coding Sys--Current   **NAACCR Item #2120**
Field Length: 1 character   **Source of Standard: NAACCR**

Documentation under topic "Rationale" was updated to state: " This item will no longer be required by SEER. Also, the topic "Codes" was updated to add a new code I. The code updates and additions are as follows:

Codes

I	2021 SEER Coding Manual

SEER Coding Sys--Original   **NAACCR Item #2130**
Field Length: 1 character   **Source of Standard: NAACCR**

Documentation under topic "Rationale" was updated to state: "This item will no longer be required by SEER. Also, the topic "Codes" was updated to add a new code I. The code updates and additions are as follows:

Codes

I	2021 SEER Coding Manual

TNM Edition Number   **NAACCR Item #1060**
Field Length: 2 characters   **Source of Standard: CoC**

Documentation under topic "Codes" was updated to add a new codes 09. The code updates and additions are as follows:

Codes

09   Ninth Edition (first chapter published 2020), recommended for use with chapter-specific cases diagnosed 2021+

Site Specific Data Items (SSDIs)

Three Site-Specific Data Items, beginning with cases diagnosed 1/1/2021 have been revised in the SSDI Manual to be collected for additional Schemas. For additional information and coding instructions, please see the SSDI Manual located on the NAACCR website. The list of revised SSDI's and applicable *additional* Schemas they will be collected for are listed below for your convenience.

Site-Specific Data Items (SSDIs) – Additional Schema Collection List
Source of Standard: NAACCR

NAACCR Name	Schema	NAACCR Item #	Field Length (characters)
HER2 Overall Summary	Esophagus Squamous (00161) Esophagus (00169) Stomach (00170)	3855	1
Ki-67	NET Ampulla of Vater (00302) NET Appendix (00320) NET Colon and Rectum (00330) NET Duodenum (00301) NET Jejunum and Ileum (00310) NET Pancreas (00340) NET Stomach (00290)	3863	5
Schema Discriminator 2	Soft Tissue Abdomen and Thoracic (00421) Soft Tissue Trunk and Extremities (00410) Soft Tissue Other (00450)	3927	1

AFP Post-Orchiectomy Range   NAACCR Item #3806
Field Length: 1 character   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to add new code 5. The code updates and additions are as follows:

Codes

5   Post-Orchiectomy alpha fetoprotein (AFP) unknown or not done but pre-orchiectomy AFP was normal

Estrogen Receptor Percent Positive or Range   NAACCR Item #3826
Field Length: 3 characters   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to add new code XX7. The code updates and additions are as follows:

Codes

XX7   Test done, results not in chart

Estrogen Receptor Summary   **NAACCR Item #3827**
Field Length: 1 character   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to add new note to code 0. The code updates and additions are as follows:

Codes

0   ER negative (0.0% or less than 1%)

Extranodal Extension Clin (Non-Head and Neck)   **NAACCR Item #3830**
Field Length: 1 character   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to add a new code 4. The code updates and additions are as follows:

Codes

4   Regional lymph nodes involved, ENE present/identified, unknown how identified

Extranodal Extension Head and Neck Clinical   **NAACCR Item #3831**
Field Length: 1 character   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to add a new code 4. The code updates and additions are as follows:

Codes

4   Regional lymph nodes involved, ENE present/identified, unknown how identified

Fibrosis Score   **NAACCR Item #3835**
Field Length: 1 character   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to revise code 0 and code 1. The code updates and additions are as follows:

Codes

0   Any of the following histologically confirmed

                 No to moderate fibrosis

                 Ishak fibrosis score 0-4
                 METAVIR score F0-F3
                 Batt-Ludwig score 0-3

1   Any of the following histologically confirmed

                 Advanced/severe fibrosis
                 Developing cirrhosis
                 Incomplete cirrhosis
                 Transition to cirrhosis
                 Cirrhosis, probable or definite
                 Cirrhosis, NOS

Ishak fibrosis score 5-6>
METAVIR score F4
Batt-Ludwig score 4

FIGO Stage   **NAACCR Item #3836**

Field Length: 5 characters   **Source of Standard: NAACCR**

The field length has been updated from 2 to 5. Allowable values have been modified from using a two digit code to store the actual stage value. Code changes for SSDIs are applicable to cases diagnosed January 1, 2018 forward, but registrars will not be required to update previously coded information.

Codes

1	FIGO Stage I
1A	FIGO Stage IA
1A1	FIGO Stage IA1
1A2	FIGO Stage IA2
1B	FIGO Stage IB
1B1	FIGO Stage IB1
1B2	FIGO Stage IB2
1B3	FIGO Stage IB3
1C	FIGO Stage IC
1C1	FIGO Stage IC1
1C2	FIGO Stage IC2
1C3	FIGO Stage IC3
2	FIGO Stage II
2A	FIGO Stage IIA
2A1	FIGO Stage IIA1
2A2	FIGO Stage IIA2
2B	FIGO Stage IIB
3	FIGO Stage III
3A	FIGO Stage IIIA
3A1	FIGO Stage IIIA1
3A11	FIGO Stage IIIAi
3A12	FIGO Stage IIIAii
3A2	FIGO Stage IIIA2
3B	FIGO Stage IIIB
3C	FIGO Stage IIIC
3C1	FIGO Stage IIIC1
3C2	FIGO Stage IIIC2
4	FIGO Stage IV
4A	FIGO Stage IVA
4B	FIGO Stage IVB
98	Not applicable: Information not collected for this case
	If this item is required by your standard setter, use of code 98 will result in an edit error.)
99	Not documented in medical record
	FIGO stage unknown, not assessed or unknown if assessed

Gleason Patterns Clinical   **NAACCR Item #3838**

Field Length: 2 characters   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to revise codes X6 and X9. The code updates and additions are as follows:

Codes

X6	TURP and/or Biopsy done, primary pattern unknown, secondary pattern unknown
X9	Not documented in medical record
	Gleason Patterns Clinical not assessed or unknown if assessed. Unknown if TURP and or biopsy done

Gleason Patterns Pathological   NAACCR Item #3839
Field Length: 2 characters   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to revise codes X6 and X9. The code updates and additions are as follows:

Codes

X6	Prostatectomy done, primary pattern unknown, secondary pattern unknown
X9	Not documented in medical record
	Gleason Patterns Clinical not assessed or unknown if assessed. Unknown if Prostatectomy done

HCG Post-Orchiectomy Range   NAACCR Item #3847
Field Length: 1 character   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to add new code 5. The code updates and additions are as follows:

Codes

5	Post-Orchiectomy human chronic gonadotropin (hCG) unknown or not done but pre-orchiectomy hCG was normal

HER2 ISH Dual Probe Copy Number   NAACCR Item #3851
Field Length: 4 characters   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to revise code XX.9. The code updates and additions are as follows:

Codes

XX.9	Not documented in medical record
	Results cannot be determined (indeterminate)
	Dual probe test not done; only single probe test performed
	HER2 ISH Dual Probe Copy Number not assessed or unknown if assessed

HER2 ISH Dual Probe Ratio   NAACCR Item #3852
Field Length: 4 characters   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to revise code XX.9. The code updates and additions are as follows:

Codes

XX.9	Not documented in medical record
	Results cannot be determined (indeterminate)
	Dual probe test not done; only single probe test performed

HER2 ISH Single Probe Copy Number   NAACCR Item #3853
Field Length: 4 characters   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to revise code XX.9. The code updates and additions are as follows:

Codes

    XX.9   Not documented in medical record
                    Results cannot be determined (indeterminate)
                    Single probe test not done; only dual probe test performed
                    HER2 ISH Single Probe Copy Number not assessed or unknown if assessed

HER2 Overall Summary   NAACCR Item #3855
Field Length: 1 character   **Source of Standard: NAACCR**

Documentation under topic "Rational" was updated to add clarification. Also, additional schemas will now collect this data item. The updates and additions are as follows:

Rationale
This data item is required for prognostic stage grouping in AJCC 8th edition, Chapter 48, *Breast*. It was previously collected as Breast, CS SSF # 15.Experts recommend that every invasive breast cancer be tested for the presence of HER2 because anti-HER2 treatments are highly effective for these tumors.

HER2 overall summary It will be collected for Esophagus and Esophagogastric Junction and Stomach for cases diagnosed 1/1/21+ because NCCN guidelines recommend HER2 testing at time of diagnosis if patients are documented or suspected of having metastatic disease. HER2 monoclonal antibodies may be added to chemotherapy for patients with HER2 positive disease.

Additionally, this data item will now be collected for additional schemas, please see the Additional Schema Collection List.

KI-67   NAACCR Item #3863
Field Length: 5 characters   **Source of Standard: NAACCR**

Documentation under topics "Description" and "Rational" were updated to add clarification. There are three new codes added, XXX.4, XXX.5, and XXX.6. Also, additional schemas will now collect this data item. The updates and additions are as follows:

Description
Ki-67 (MIB-1) (Proliferative Index) is a marker of cell proliferation. A high value indicates a tumor that is proliferating more rapidly. Codes and coding instructions for this data item are site-specific.

Rationale
Ki-67 (MIB-1) (Proliferative Index) is a Registry Data Collection Variable in AJCC. It was a new data item for breast cases diagnosed 1/1/2018+. It will apply to neuroendocrine tumors (NET) of the gastrointestinal tract (AJCC Chapters 29 – 34) for cases diagnosed 1/1/2021+. High Ki-67 is an adverse prognostic factor and Ki-67 is a component of grade for these tumors. NCCN guidelines recommend that tumor differentiation, mitotic rate and Ki-67 should be recorded in the pathology report for these tumors.

Codes

XXX.4	Ki-67 stated as less than 3%
XXX.5	Ki-67 stated as 3%-20%
XXX.6	Ki-67 stated as greater than 20%

Additionally, this data item will now be collected for additional schemas, please see the [Additional Schema Collection List](#).

KRAS   NAACCR Item #3866
Field Length: 1 character   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to revise code 0. The code updates and additions are as follows:

Codes

0	Normal
	KRAS negative, KRAS wild type
	Negative for (somatic) mutations, no alterations, no (somatic) mutations identified, not present, not detected

LDH Lab Value   NAACCR Item #3932
Field Length: 7 characters   **Source of Standard: NAACCR**

Name changed from LDH Pretreatment Lab Value to LDH Lab Value to clarify that LDH may be measured before or after surgical resection. The word "Pretreatment" was removed from the "Description" and "Rationale" paragraphs.

LDH Level   NAACCR Item #3869
Field Length: 1 character   **Source of Standard: NAACCR**

Name changed from LDH Pretreatment Level to LDH Level to clarify that LDH may be measured before or after surgical resection.

LDH Post-Orchiectomy Range   NAACCR Item #3867
Field Length: 1 character   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to add a new code 5. The code updates and additions are as follows:

Codes

5	Post-Orchiectomy lactate dehydrogenase (LDH) unknown or not done but pre-orchiectomy LDH was normal

Microsatellite Instability (MSI)   NAACCR Item #3890
Field Length: 1 character   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to revise codes 0 and 2. The code updates and additions are as follows:

Codes

0	Microsatellite instability (MSI) stable; microsatellite stable (MSS); negative, NOS AND/OR
	Mismatch repair (MMR) intact, no loss of nuclear expression of MMR proteins
	MMR proficient (pMMR or MMR-P)

2	MSI unstable high (MSI-H)
	AND/OR
	MMR deficient (dMMR or MMR-D), loss of nuclear expression of one or more MMR proteins

Number of Examined Para-Aortic Nodes   NAACCR Item #3899

Field Length: 2 characters   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to revise code X9. The code updates and additions are as follows:

Codes

X9	Not documented in patient record
	Cannot be determined, indeterminate if positive para-aortic nodes present
	No lymph node dissection performed
	Para-aortic lymph nodes not assessed or unknown if assessed

Number of Examined Pelvic Nodes   NAACCR Item #3900

Field Length: 2 characters   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to revise code X9. The code updates and additions are as follows:

Codes

X9	Not documented in patient record
	Cannot be determined, indeterminate if positive pelvic nodes present
	No lymph node dissection performed
	Pelvic lymph nodes not assessed or unknown if assessed

Number of Positive Para-Aortic Nodes   NAACCR Item #3901

Field Length: 2 characters   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to revise code X9. The code updates and additions are as follows:

Codes

X9	Not documented in patient record
	Cannot be determined, indeterminate if positive para-aortic nodes present
	No lymph node dissection performed
	Para-aortic lymph nodes not assessed or unknown if assessed

Number of Positive Pelvic Nodes   NAACCR Item #3902

Field Length: 2 characters   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to revise code X9. The code updates and additions are as follows:

Codes

X9	Not documented in patient record
	Cannot be determined, indeterminate if positive pelvic nodes present
	No lymph node dissection performed
	Pelvic lymph nodes not assessed or unknown if assessed

Organomegaly

NAACCR Item #3907

Field Length: 1 character　　　　　　　　　　　　　**Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to revise codes 0, 1 and 9. The code updates and additions are as follows:

Codes

0	Neither hepatomegaly (liver) nor splenomegaly (spleen) present
1	Hepatomegaly (liver) and/or splenomegaly (spleen) present
9	Not documented in medical record
	Organomegaly (hepatomegaly and/or splenomegaly) not assessed or unknown if assessed

Progesterone Receptor Percent Positive or Range

NAACCR Item #3914

Field Length: 3 characters　　　　　　　　　　　　　**Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to add a new code XX7. The code updates and additions are as follows:

Codes

XX7	Test done, results not in chart

Progesterone Receptor Summary

NAACCR Item #3915

Field Length: 1 character　　　　　　　　　　　　　**Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to revise code 0. The code updates and additions are as follows:

Codes

0	PR negative (0.0% or less than 1%)

Residual Tumor Volume Post Cytoreduction

NAACCR Item #3921

Field Length: 2 characters　　　　　　　　　　　　　**Source of Standard: NAACCR**

Allowable values have been modified. Essentially, codes 10-40 and 90-93 are being removed and codes 50, 60, 70, and 80 have been added. Codes 10 and 20 are now code 50, codes 30 and 40 are now code 60, codes 90 and 91 are now code 70, and codes 92 and 93 are now code 80. Code changes for SSDIs are applicable to cases diagnosed January 1, 2018 forward, but registrars will not be required to update previously coded information.

Codes

00	No gross residual tumor nodules
50	Residual tumor nodule(s) 1 centimeter (cm) or less
60	Residual tumor nodule(s) greater than 1 cm
70	Macroscopic residual tumor nodule(s), size not stated
80	Procedure described as optimal debulking and size of residual tumor nodule(s) not given
97	No cytoreductive surgery performed
98	Not applicable: Information not collected for this case
	(If this item is required by your standard setter, use of code 98 will result in an edit error.)
99	Not documented in medical record
	Residual tumor status after cytoreductive surgery not assessed or unknown if assessed

S Category Pathological   NAACCR Item #3924
Field Length: 1 character   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to add new code 5. The code updates and additions are as follows:

Codes

5	Post-Orchiectomy serum tumor markers unknown or not done but pre-orchiectomy serum tumor markers were normal

Schema Discriminator 2   NAACCR Item #3927
Field Length: 1 character   **Source of Standard: NAACCR**

This data item will now be collected for additional schemas, please see the Additional Schema Collection List.

Tumor Growth Pattern   NAACCR Item #3935
Field Length: 1 character   **Source of Standard: NAACCR**

Documentation under topic "Codes" was updated to revise code 9. The code updates and additions are as follows:

Codes

9	Not documented in medical record Radiology and/or pathology report does not mention tumor growth pattern Cannot be determined by the pathologist Tumor growth pattern not assessed or unknown if assessed

Visceral and Parietal Pleural Infusion   NAACCR Item #3937
Field Length: 1 character   **Source of Standard: NAACCR**

Allowable values have been modified. Essentially, codes 1, 2 and 3 are being removed and code 5 has been added. In addition, Additionally, Codes 1 and 2 are being collapsed into code 4, and code 3 has been moved to code 5. Code changes for SSDIs are applicable to cases diagnosed January 1, 2018 forward, but registrars will not be required to update previously coded information.

Codes

0	No evidence of visceral pleural invasion identified Tumor does not completely traverse the elastic layer of the pleura Stated as PL0
4	Invasion of visceral pleural present, NOS Stated as PL1 or PL2
5	Tumor invades into or through the parietal pleural OR chest wall Stated as PL3 Conversions that will be implemented: **Code 1 cases:** Now code 4 **Code 2 cases:** Now code 4 **Code 3 cases:** Now code 5
6	Tumor extends to pleura, NOS; not stated if visceral or parietal
8	Not applicable: Information not collected for this case If this item is required by your standard setter, use of code 8 will result in an edit error.)

9	Not documented in medical record
	No surgical resection of primary site is performed
	Visceral Pleural Invasion not assessed or unknown if assessed or cannot be determined

NAACCR RETIRED (Retired Data Items):

Beginning with cases diagnosed 1/1/2021, the following data items have been retired in the NAACCR Volume II, Standards and Data Dictionary.

Retired Data Items – List
Source of Standard: N/A

NAACCR Name	NAACCR Item #
Reserved 00	37
Reserved 01	370
Reserved 02	530
Reserved 03	680
Reserved 04	750
Reserved 05	1180
Reserved 06	1190
Reserved 07	1300
Reserved 08	1650
Reserved 09	1740
Reserved 10	1835
Reserved 11	1900
Reserved 12	2510
Reserved 13	2080
Reserved 14	2210
Reserved 15	2400
Reserved 16	2450
Reserved 17	2700

ADDITIONAL UPDATES (other Volume I related items for cases diagnosed January 1, 2021 and forward):

CCR Updates

Please see the CCR requirements listed below for cases diagnosed January 1, 2021 and forward.

Reportability:

Reportability for cases diagnosed January 1, 2021 and forward, is based on the ICD-O-Third Edition, Second Revision Morphology (ICD-O-3.2). This will include updates regarding behavior and reportability. Please see the ICD-O-3 Implementation Guidelines located on the NAACCR website for the 2021 ICD-O-3.2 Coding Guidelines and associated tables.

  ➢ Table 1: Behavior code changes- non-reportable to reportable
  ➢ Table 2: Behavior code changes- reportable to non-reportable

- Table 3: Deleted codes- histology terms moved to other codes
- Table 4: Change in reportable terminology
- Table 5: New codes and terms
- Table 6: Tables 1-5 plus new preferred & related terms, synonyms - Numerical order
- Table 7: Tables 1-5 plus new preferred & related terms, synonyms - Alphabetical order

The following changes are also applicable for cases diagnosed in January 1, 2021.
- Early or evolving melanoma in situ, or any other early or evolving melanoma, is reportable.
- All GIST tumors are reportable and classified as 8936/3 in ICD-O-3.2.
- Nearly all thymomas are reportable; the exceptions are microscopic thymoma or thymoma benign (8580/0), micronodular thymoma with lymphoid stroma (8580/1), and ectopic hamartomatous thymoma (8587/0).

Staging:
The CCR Staging requirements for cases diagnosed January 1, 2021 and forward are as follows:
- AJCC TNM 8th edition directly assigned required by CoC facilities, as available by non-CoC
- EOD 2018 required by all facilities
- Summary Stage 2018 directly coded required by all facilities

Other:
At this time, CCR will require the collection of the four NCDB COVID-19 data items.

Visual Editing:
The list of visually edited data items for 2021 will be distributed and posted to the CCR website in the near future.

References:
The following manuals are appropriate reference documents for cases diagnosed 1/1/2021 and forward.

- CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES FOR HOSPITALS: California Cancer Reporting System Standards, Volume I – 2021

- American Joint Commission on Cancer (AJCC) 8th Edition
  - Refer to the AJCC 8th Edition Updates and Corrections for updates to the AJCC 8th Edition. It can also be found on the AJCC website: https://cancerstaging.org/
  - Cervix 9th Version

- 2021 STandards for Oncology Registry Entry (STORE) Manual – Release planned to be by November 1, 2020. Please see the 2021 Implementation Guidelines and Recommendations, Appendix C, for a list of items that will be removed from the STORE Manual.

- SEER Program Coding and Staging Manual 2021 – Published September 1, 2020. Please see the Summary of Changes document containing updates made between the 2018 and 2021 Manuals.

- 2018 Solid Tumor Coding Manual – Release to be determined.
  - The eight site groups which were updated in 2018 will include minor updates for 2021 and will **not** require review of previously abstracted cases.

- New histologies, codes, and terms from ICD-O-3.2 and the 2021 ICD-O Update added to tables
- Corrections to histology tables
- Additional H rules to enforce correct histology coding
- Clarification of coding histology prior to neo-adjuvant therapy
- Clarification to Malignant and Benign CNS Terms & Definitions: WHO Grade II and behavior
- Additional notes and examples

- Cutaneous Melanoma Solid Tumor rule has been updated for cases diagnosed January 1, 2021 forward.
  - Rule available in text format only
  - Histology table updated to include WHO 4th Ed Skin Tumors, 2021 ICD-O update, and ICD-O-3.2
  - Terms and Definitions are now included with the M-rules and H-rules
  - New table for coding primary site and laterality
  - Reportable and non-reportable histology tables
- Other Sites rules are currently being revised. Continue to apply the 2007 MP/H Other Sites Rules for cases diagnosed January 1, 2007 through December 31, 2021.

➤ 2018 Site-Specific Data Item (SSDI) Manual, Version 2.0 – Published September 2020.
  - Code and code descriptions were updated on some SSDI's, to improve clarity due to changes in clinical management and/or staging or to address questions that were raised in the various forums.
  - Code changes for SSDIs are applicable to cases diagnosed January 1, 2018 forward, but registrars will not be required to update previously coded information.

➤ Grade Coding Instructions and Tables, Version 2.0 – Published September 2020.
  NOTES: For Grade Clinical, Grade Pathological, Grade Post Therapy Path (yp), Grade Post Therapy Clin (yc) updates to the following schemas have been made.
  - Lacrimal Gland - Grade fields have been modified. Essentially, codes A-D have been removed and Code 4 has been added. Code 1 and Code A both mean well differentiated, and similarly for codes 2 and B, codes 3 and C, it was decided to streamline the available codes. Code 4 was added to capture the Undifferentiated, anaplastic cases.
  - Lymphoma Ocular Adnexa – Grade fields have been modified. Essentially, codes 5 and L have been removed and revisions have been made to the text of Codes 3 and 4. Code 3 is now G3, more than 15 centroblasts per 10 HPF but with admixed centrocytes. Cases that used to have Code 4 should be changed to Code 3. Code 4 is now G4, more than 15 centroblasts per 10 HPF but without centrocytes. Cases that used to have Code 5 should be changed to Code 4. Code L, Low Grade (1 or 2) was determined to be a variation of Unknown, so cases that used to have L should be changed to Code 9.
  - New notes have been added. Due to these additions, many of the note numbers have changed. These updates can be applied to cases diagnosed January 1, 2018 forward; however, registrars are not required to update previously coded grade information based on the new notes.

➤ The Hematopoietic and Lymphoid Neoplasm Database – Updated September 2020.
  Modifications include:
  - Histology Changes
  - Reportability Changes

- Coding Diagnostic Confirmation
- Diagnostic Confirmation Coding Instructions for Hematopoietic Lymphoid Neoplasms (9590/3-9993/3)
- New Appendix D - Introduction to Genetic Nomenclature

Please see the Revision History for the [Hematopoietic Project, 2020 Changes](#)

- ➢ [SEER Summary Stage 2018, Version 2.0](#) – Published September 2020.
  Summary Stage 2018 staging system will continue to be used for cases diagnosed on or after January 1, 2021. Please see the [Revision History, Change Log](#) containing updates made between version 1.7 and 2.0.

- ➢ [Extent of Disease (EOD) 2018 General Coding Instructions](#) – Updated September 2020.
  EOD 2018 staging system will continue to be used for cases diagnosed on or after January 1, 2021. Please see the [EOD Change Log](#) containing updates made between version 1.7 and 2.0.

AJCC Updates

The AJCC will be shifting from a *Cancer Staging Manual* to a *Cancer Staging System* and moving away from *Editions*, to *Versions* which better align with software development and how users are increasingly consuming AJCC content.

- Version 9 of the Cervix Uteri Cancer Staging System will go into effect January 1, 2021.

CDC NPCR Updates

Beginning with cases diagnosed January 1, 2021 and forward, CDC-NPCR will adopt the new record format and data collection requirements as published in the Data Standards and Data Dictionary, Version 21.

- CDC NPCR will require directly assigned Summary Stage 2018 (most current version).
- Use the most current versions available if voluntarily reporting:
  o 2018 EOD
  o SEER*RSA
  o ICD-O-3 2021
  o AJCC-TNM.
- CDC is following the NAACCR Guidelines for ICD-O-3 Update Implementation (published for 2021).

CoC Updates

Beginning with cases diagnosed January 1, 2021 and forward, all CoC accredited programs should follow the rules and instructions in STORE v2021.

- o The revised STORE Manual is planned to be released by November 1, 2020.
- o Data collection of:
  - New data items for collection when available include: the AJCC Post Therapy Clin (yc) T, N, and M stage classification (yc stage group is not yet available)
  - Updated radiation treatment modality code for Phase I; all SSDI's except NAACCR 3850, 3851, 3852, 3853, 3854, 3859, and 3919; and, allowable values U, Z75.2, and Z75.3 for secondary diagnosis 1-10 [3780, 3782, 3784, 3786, 3788, 3790, 3792, 3794, 3796, 3798].
  - To evaluate the impact of SARSCoV2 diagnosis on cancer patients, CoC accredited facilities will collect the 4 new data items listed in section 2.6. These data items will be collected for cases diagnosed January 1, 2020 through December 31, 2021.
- o Questions related to STORE can be submitted to ncdb@facs.orgv or the [CA Forum](#).

- In an effort to make the STORE Manual more reflective of the needs of CoC hospital registrars and the NCDB, data items defined in the STORE Manual that are not collected by the NCDB or are otherwise out of use by the NCDB were identified for removal. Removed data items that will continue to be collected by other standards setters will have their definitions added to their respective manuals.

ICD-O-3 Updates

ICD-O-Third Edition, Second Revision Morphology (ICD-O-3.2) is being implemented in 2021 and will align the cancer surveillance community with the current WHO Classification of Tumors used by physicians. AJCC and NCI SEER will work closely together to implement ICD-O-3.2 to minimize issues affecting cancer registrars. This implementation is required for cases diagnosed January 1, 2021 and forward and includes updates regarding behavior and reportability. Please see the ICD-O-3 Implementation Guidelines located on the NAACCR website for the 2021 ICD-O-3.2 Coding Guidelines and associated tables.

NAACCR Updates

As part of the 2021 update, the NAACCR XML Data Exchange Standard was adopted as the standard transmission format, and the NAACCR fixed-width format has been retired. This change affects many operations, such as the transmission and processing of records received from reporting facilities, implementation of edits software, and the reporting of data from central registries to standard setters. See NAACCR Data Exchange Standard, XML Specifications for Cancer Registry Records for more details about XML.

SEER Updates

NCI SEER expects all cases diagnosed in year 2021 and thereafter will be transmitted by central registries to NCI in NAACCR version 21.

- ➢ Requirements include:
  - o EOD 2018
  - o Summary Stage 2018 will be derived using EOD information.
  - o The AJCC TNM data items are required when available.
  - o NCI SEER requires collection and transmission of the new Neoadjuvant Data Items [1632, 1633, and 1634] for cases diagnosed January 1, 2021 and later.
- The most up-to-date version of the SEER Registrar Staging Assistant (SEER*RSA) can be found at https://seer.cancer.gov/tools/staging/rsa.html.
- Questions regarding the SEER Program Coding Manual, Summary Stage 2018 and EOD should be directed to Ask a SEER Registrar at: https://seer.cancer.gov/registrars/contact.html
- The SEER Site/Histology Validation List, used in software and edit development, has been updated to include the new ICD-O-3.2 code and behavior changes per the 2021 ICD-O-3.2 updates. This site/histology list is provided in both PDF and Excel formats. Please see https://seer.cancer.gov/icd-o-3/